Anthracene based compounds as new L-type Ca2+ channel blockers: design, synthesis, and full biological profile

Journal of Medicinal Chemistry
Sergio BovaAlessandra Bisi


L-Type Ca(2+) channels (LTCCs) play a key role in the regulation of vascular smooth muscle contraction, and substances that interfere with their function (Ca(2+) channel blockers) are widely used in the therapy of hypertension. Here, we report anthracene-maleimide derivatives as new LTCC blockers. Among these, 3, lacking intracellular effects, was investigated in more detail. The results show that 3 binds preferentially to inactivated LTCCs, directly interacting with the pore-forming subunit of the channel.


Jan 1, 1990·Reviews of Physiology, Biochemistry and Pharmacology·H Glossmann, J Striessnig
Jan 1, 1990·Trends in Pharmacological Sciences·G Zernig
Apr 1, 1994·The Journal of Pharmacy and Pharmacology·A M Gurney
May 19, 1998·Trends in Pharmacological Sciences·J StriessnigH Glossmann
Oct 9, 1998·The Journal of Biological Chemistry·R L KrausJ Striessnig
Oct 14, 2000·Annual Review of Cell and Developmental Biology·W A Catterall
Aug 18, 2001·Journal of Applied Physiology·K M Sanders
Apr 6, 2002·British Journal of Pharmacology·Simona SaponaraFabio Fusi
Jun 12, 2003·European Journal of Pharmacology·Sergio BovaFabio Fusi
Dec 6, 2003·Pharmacological Reviews·David E ClaphamUNKNOWN International Union of Pharmacology

❮ Previous
Next ❯


Mar 8, 2013·Acta Crystallographica. Section E, Structure Reports Online·Barbara MiroslawMarta Struga
Jan 18, 2015·European Journal of Medicinal Chemistry·Alessandra BisiConcettina Cappadone
May 31, 2017·Vaccines·Christopher ConchaCristian Ibáñez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.